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Endothelial inﬂammation plays a critical role in the development and progression of cardiovascular
disease, albeit the mechanisms need to be fully elucidated. We here report that treatment of human
umbilical vein endothelial cells (HUVECs) with tumor necrosis factor (TNF) a substantially increased
the expression of MCP-induced protein 1 (MCPIP1). Overexpression of MCPIP1 protected ECs against
TNFa-induced endothelial activation, as characterized by the attenuation in the expression of the
adhesion molecule VCAM-1 and monocyte adherence to ECs. Conversely, small interfering RNA-
mediated knock down of MCPIP1 increased the expression of VCAM-1 and monocytic adherence
to ECs. These studies identiﬁed MCPIP1 as a feedback control of cytokines-induced endothelial
inﬂammation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A crucial step in atherogenesis is the arterial recruitment of
inﬂammatory cells from the circulation and their transendothelial
migration into the subendothelial space of large arteries where
they differentiate into macrophages and become functionally ac-
tive [1,2]. In response to inﬂammatory stimuli, such as tumor
necrosis factor a (TNFa), interleukin 1b (IL)-1b, and interferon c,
endothelial cells (ECs) undergo inﬂammatory activation, resulting
in an increased surface expression of cell adhesion molecules, such
as vascular cell adhesion molecule (VCAM)-1, intercellular adhe-
sion molecule (ICAM)-1, and E-selectin, which contributes to the
recruitment of inﬂammatory cells to arterial wall and their trans-chemical Societies. Published by E
UVECs, human umbilical vein
M-1, vascular cell adhesion
-1; NF-jB, nuclear factor-jB;
ocyte chemotactic protein 1;
Center & Department of Basic
Missouri Kansas City. 2411
16 235 6444.migration across the wall [3,4]. The activated ECs also secret cyto-
kines and chemokines such as monocyte chemotactic protein 1
(MCP-1), which is a potent inducer for monocyte attachment to
ECs and migration into subendothelial space [5,6]. Mice deﬁcient
in MCP-1 or its receptor CCR2 had signiﬁcant reduced atheroscle-
rotic lesions, suggesting that MCP-1/CCR2 interaction has a role
in monocyte recruitment in atherosclerosis [7,8].
MCP-induced protein 1 (MCPIP1, also known as ZC3H12A) is a
recently identiﬁed gene in human peripheral blood monocytes
treated with MCP-1 [9,10]. The gene undergoes rapid and potent
transcription induction upon stimulation with proinﬂammatory
molecules, such as TNFa, MCP-1, IL-1b and lipopolysaccharide
(LPS) [9–13]. Further studies showed that MCPIP1 plays an impor-
tant role in both physiological and pathological processes related
to inﬂammation [10,11]. In the experiments on cultured cells,
MCPIP1 was proved to be a negative regulator of macrophage acti-
vation [10]. In a recent report on mice, MCPIP1 deﬁciency leads to a
complex phenotype including severe anemia, autoimmune re-
sponse and severe inﬂammatory response and most mice died
within 12 weeks of birth [11]. These results suggest that MCPIP1
may critically control inﬂammation and immunity and would be
a potential therapeutic target for treatment of human inﬂamma-
tory diseases such as atherosclerosis.lsevier B.V. All rights reserved.
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inﬂammatory cytokines TNFa and IL-1b and that overexpression of
MCPIP1 suppresses cytokine-induced expression of VCAM-1, as
well as monocyte adhesion to human ECs. These results indicate
that MCPIP1 also negatively regulates proinﬂammatory activation
of vascular ECs.2. Materials and methods
2.1. Cell culture and reagents
Human umbilical vein endothelial cells (HUVECs) and human
CD14+ monocytes were acquired from Lonza Walkersville Inc.
(Walkersville, MD) and cultured in EC basal medium-2 and lym-
phocyte growth media-3 respectively according to the manufac-
turer instructions. The human acute monocytic leukemia cell line
THP-1 was obtained from American Type Culture Collection and
was maintained as described previously [10]. Human MCPIP1
expression plasmid was described previously [10]. Human
VCAM-1-Luc plasmid was originally generated by Dr. W.C. Aird’s
Laboratory (Beth Israel Deaconess Medical Center, Boston) and
kindly provided by Dr. Mukesh K. Jain (Case Western Reserve Uni-
versity, Cleveland, Ref. [14]). The MCPIP1 rabbit polyclonal anti-
body was described previously [10]. VCAM-1 (sc-13160) and
actin antibody were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). PAI-1, iNOS and ICAM-1 antibodies were from Cell
Signaling Technology. Anti-VCAM-1-Fluorescein, anti-ICAM-1-
Fluorescein and VCAM-1 monoclonal antibody were purchased
from R&D Systems, Inc. Human recombinant TNFa, IL-1b and acti-
nomycin D were purchased from Sigma (Saint Louis, MI).
2.2. Immunohistochemistry
Adult, male C57BL/6 wild-type and ApoE/mice were fed with
high-cholesterol diet for 4 weeks. Arterial segments were isolated
and ﬁxed in 4% paraformaldehyde. Parafﬁn (5 lm) sections were
immunostained with rabbit anti human MCPIP1 antibody using
the avidin-biotin peroxidase method. This investigation has been
approved by the animal use and care committee of Peking Univer-
sity Health Science Center and conforms with the Guide for the
Care and Use of Laboratory Animals published by the US National
Institute of Health.
Human atherosclerotic plaque tissue was collected from an
anonymous patient with consent as described in an approved
human subject protocol from the UCSB Human Subjects Commit-
tee in coordination with Cottage Hospital (Study number 06-59)
and conforms to the principles outlined in the ‘‘Declaration of
Helsinki”. Human atherosclerotic sections were co-stained with
1:50 diluted rabbit anti human MCIPIP1 antibody (GeneTex,
GTX110807) and 1:100 diluted FITC conjugated moue anti-smooth
muscle cell (SMC)-Actin antibody (Sigma, F3777) or FITC conju-
gated anti-CD31, followed by incubation with Alexa ﬂuor 568 con-
jugated goat anti rabbit IgG antibody (Invitrogen, A11036). Images
were taken using Samsun Fluoview confocol system using the no
primary slides as negative control.
2.3. Measurement of cell-surface expression of adhesion molecules
The cell-surface expressions of VCAM-1 and ICAM-1 on HUVECs
were performed essentially as described [15] but with some mod-
iﬁcations using cell ELISA. HUVECs were seeded in 96-well plate
and transfected with HA-MCPIP1 or control vector using transPass
HUVEC transfection reagent (NEB). 24 h later the cells were stimu-
lated with TNFa for overnight. The stimulated cells were washed
with PBS and ﬁxed with 4% (v/v) paraformaldehyde for 30 min at4 C. FBS (1% (v/v) in PBS) was used as a blocking reagent. After
washing with PBS, cells were incubated with FITC conjugated
anti-VCAM-1 or anti-ICAM-1 monoclonal antibody for 1 h at 4 C.
The cell-surface expressions of VCAM-1 and ICAM-1 were mea-
sured with a ﬂuorometer (Flx800, BioTek Instrument, Inc.) at
485 nm excitation wavelength and 535 nm emission wavelength.
2.4. Western blot and Q-PCR
HUVECs were transfected with MCPIP1-EGFP or HA-MCPIP1 as
well as their control vectors by electroporation using Amaxa Elec-
troporation Unit following the manufacturer’s instruction. 24 h la-
ter, the transfected cells were exposed to the indicated stimuli.
Total protein or RNA was harvested for Western blot or Q-PCR
analysis as described previously [10].
2.5. Luciferase assay
HUVECs were seeded into 12-well plate and transfected with
Fugene 6 Transfection Reagent (Roche Applied Science) following
the manufacturer’s instruction. The total amount of plasmid DNA
was kept constant within each experiment. Luciferase activity
was measured by luciferase Assay System (Promega) and normal-
ized to b-galactosidase activity by cotransfecting the pCMV-bgal
plasmid in all experiments. All transfections were performed in
triplicate and at least repeated two times.
2.6. mRNA stability assay
HUVECs were transfected with MCPIP1-EGFP or EGFP control
vector by electroporation. After 8 h stimulation with TNFa
(10 ng/ml), transcription was stopped by adding 5 lg/ml actino-
mycin D. The cells were harvested and RNA was isolated at differ-
ent time points as indicated. The mRNA levels of VCAM-1 were
measured by Northern blot as described previously [10].
2.7. Short-interfering RNA
The pre-designed siRNA targeting to human MCPIP1 as well as
its negative control were purchased from Santa Cruz Biotech.
(CA). The siRNA was transfected into HUVECs by electroporation
using Amaxa Electroporation Unit following the manufacturer’s
instruction. 24 h later, the cells were treated with or without
TNFa (10 ng/ml) for 8 h. Then the cells were harvested and protein
was isolated to assess for MCPIP1 knockdown and VCAM-1
expression.
2.8. Monocyte adhesion assay
THP-1 cells or human CD14+ monocytes were labeled with ﬂuo-
rescein isothiocyanate using a PKH67 ﬂuorescent staining kit (Zyn-
axis, Inc., Malvern, PA) according to the instructions of the
manufacturer. After the HUVECs were stimulated and washed,
2.5  105 ﬂuorescein isothiocyanate-labeled THP-1 cells were
added to each well and allowed to interact for 60 min at 37 C. Un-
bound cells were removed by gently washing with cold PBS.
Images were taken using a Nikon Fluorescence Microscopy (Zeiss,
Thornwood, NY). Adherent cells were lysed with 50 mmol/l Tris
(pH 8.4)/0.1% sodium dodecyl sulfate, and the ﬂuorescence was
measured by a ﬂuorometry.
2.9. Statistics
Data were expressed as mean ± S.D. For comparison between
two groups, the unpaired Student’s test was used. For multiple
comparisons, analysis of variance followed by unpaired
Y. Qi et al. / FEBS Letters 584 (2010) 3065–3072 3067Student’s test was used. A value of P < 0.05 was considered
signiﬁcant.
3. Results
3.1. Expression of MCPIP1 in human and mouse atherosclerotic
lesion
To investigate whether MCPIP1 expression might be relavant to
atherosclerosis, we examined MCPIP1 expression in mouse and hu-
man atherosclerotic lesions. As shown in Fig. 1A, in the artery wall
from C57BL/6 wild-type mice, no positive staining was showed
with MCPIP1 antibody. However, MCPIP1 expression was signiﬁ-
cant increased in the atherosclerotic plaque (especially in endothe-
lial layer) from ApoE/ mice. Consistently, MCPIP1 mRNA was
increased by 2.5 folds in the aorta from ApoE/ mice compared
with that from C57BL/6 wild-type mice (Fig. 1B). High expression
of MCPIP1 can also be identiﬁed in human atherosclerotic lesions,
in which most of MCPIP1 positive cells are smooth muscle cell spe-
ciﬁc marker SM actin positive (Fig. 1C). Some CD31 positive cells
also expressed MCPIP1 in human atherosclerotic lesions (Fig. 1D).
These results indicated that smooth muscle cells are the major
population responsible for MCPIP1 expression in human athero-Fig. 1. Expression analysis of MCPIP1 in mouse and human atherosclerotic lesions. (A)
antibody. Three segments showed similar results. (B) MCPIP1 mRNA level in aorta from C
6 group. (C) Immunoﬂuorescence staining with anti-MCPIP1 antibody (1:50, red), and a
nuclear staining (Dapi, blue) of the human carotid atherosclerotic lesion were perform
concentration of anti-MCPIP1 antibody. (D) Immunoﬂuorescence staining with anti-MCP
staining (Dapi, blue) of the human carotid atherosclerotic lesion were performed.sclerotic lesion, although this protein may also be expressed by
other cell types such as ECs.
3.2. Upregulation of MCPIP1 by inﬂammatory cytokines in human ECs
To investigate the role of MCPIP1 in vascular ECs, we examined
the expression of MCPIP1 in HUVECs in response to TNFa, IL-1b,
LPS and oxLDL stimulation. Similar to macrophages, we found that
TNFa, IL-1b and LPS, but not oxLDL strongly upregulated MCPIP1
expression in HUVECs, as determined by Western blot analysis
(Fig. 2A). Further study showed that TNFa-induced MCPIP1 expres-
sion in HUVECs in a time- and dose-dependent manner. The time
course of MCPIP1 expression, when incubated with 10 ng/mL
TNFa, showed a maximal induction of MCPIP1 expression 8 h after
TNFa addition (Fig. 2B). At the concentration of as low as 2.5 ng/
mL, TNFa-induced MCPIP1 protein expression by ﬁvefold. The
maximal induction of TNFa on MCPIP1 expression was observed
at the concentration of 5 ng/mL, with increased MCPIP1 expression
by 5.5-fold (Fig. 2C). Likewise, MCPIP1 mRNA was upregulated in
HUVECs in a time-dependent fashion by TNFa, as determined by
Real-time RT-PCR (Fig. 2D). Our observation that MCPIP1 can be in-
duced in cultured ECs by TNFa or IL-1b suggests that it may regu-
late cellular responses to these stimuli.Representative photomicrographs of immunochemical staining with anti-MCPIP1
57BL/6 and ApoE/mice measured by Q-PCR. Mean ± S.D., n = 5. *P < 0.01 vs C57BL/
smooth muscle-speciﬁc marker, anti-smooth muscle actin (a-SM actin, green) and
ed. Negative control indicates non-immunized IgG matching the host species and
IP1 antibody (1:50, red), and an EC-speciﬁc marker, anti-CD31 (green) and nuclear
Fig. 2. TNFa-induced expression of MCPIP1 in HUVECs. (A) Conﬂuent HUVECs were treated with 10 ng/ml TNFa, 10 ng/ml IL-1b, 1 lg/ml LPS or 5 lg/ml OxLDL for 8 h. Total
protein was extracted, and the expression of MCPIP1 was determined by Western blot analysis. The intensity of bands was quantiﬁed by AlphaImage 2200 (AlphaInnotech,
CA) and the normalized protein levels were shown in the ﬁgure (bottom). *P < 0.01 vs untreated control. The data represent three independent experiments. (B and C)
Conﬂuent HUVECs were treated with 10 ng/ml of TNFa for indicated times (B) or treated with TNFa at the indicated concentrations for 8 h. The expression of MCPIP1 was
determined byWestern blot. *P < 0.01 vs time at 0 h or dose at 0 ng/ml. (D) Time-dependent effect of TNFa (10 ng/ml) on MCPIP1 expression as determined by Q-PCR. The top
is representative gel images. The bottom is relative mRNA level of MCPIP1 calculated by delta CT and normalized by actin mRNA level.
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HUVECs and attenuates monocyte adhesion to the activated HUVECs
Next, we examined the effects of MCPIP1 on cytokine-induced
VCAM-1 and ICAM-1 expression in HUVECs. As shown in Fig. 3A
and B, TNFa signiﬁcantly induced the cell-surface expression of
VCAM-1 and ICAM-1 by more than sixfolds in HUVECs. Overex-
pression of MCPIP1 markedly attenuated TNFa-induced expression
of VCAM-1 in a dose-dependent manner, but not affect ICAM-1
expression, as determined by cell ELISA (Fig. 3A and B). MCPIP1
overexpression did not affect HUVEC viability as determined by
trypan blue exclusion test (Fig. 3C). Western blot further conﬁrmed
that MCPIP1 overexpression suppressed TNFa-induced VCAM-1
expression, but not affect ICAM-1 expression. Meanwhile, it was
observed that PAI-1 and iNOS expression in HUVECs were also sup-
pressed by MCPIP1 (Fig. 3D). To determine the functional conse-
quence of MCPIP1’s effect on VCAM-1 expression, we examined
the effect of MCPIP1 on THP-1 and human CD14+ monocyte adhe-
sion to the activated HUVECs. When HUVECs were stimulated with
TNFa (10 ng/mL), THP-1 cell adhesion was substantially increased
and the increased adhesion of THP-1 cells to the TNFa-stimulated
HUVECs was suppressed by 50% by MCPIP1 overexpression
(Fig. 3E). Similar to THP-1 cells, TNFa-induced adhesion of human
CD14+ monocytes to HUVECs was also suppressed by MCPIP1expression in a dose-dependent manner (Fig. 3F). To determine
that VCAM-1 is critically involved in the monocyte adhasion to HU-
VECs, anti-VCAM-1 monoclonal antibody was added into the HU-
VECs. As shown in Fig. 3G, anti-VCAM-1 also dose-dependently
reduced the adhesion of human monocytes to the activated HU-
VECs. Taken together, these results further suggest that MCPIP1
functions as a negative regulator of the cytokine-induced inﬂam-
matory responses in vascular ECs.3.4. SiRNA-mediated knocking-down of MCPIP1 increases cytokine-
induced VCAM-1 expression in HUVECs and enhances THP-1 cell
adhesion to the activated HUVECs
To further study the signiﬁcance of MCPIP1 in endothelial acti-
vation, we performed loss-of-function studies, using the RNA inter-
ference technique. Transfection of MCPIP1 siRNA substantially
inhibited MCPIP1 expression by 60%, which results increased
expression of TNFa-induced VCAM-1 expression in HUVECs
(Fig. 4A and B). Furthermore, silencing of MCPIP1 expression signif-
icantly enhanced THP-1 cell adhesion to the TNF-a-activated HU-
VECs (Fig. 4C and D), further suggesting the involvement of
MCPIP1 in the regulation of cytokine-induced endothelial
activation.
Fig. 3. MCPIP1 attenuates TNFa-induced expression of VCAM-1 and the adhesion of monocytes to activated HUVECs. (A and B) HUVECs were transiently transfected with 0.1,
0.2 and 0.5 lg/well of HA-MCPIP1 or control vector by TransPass HUVEC Transfection Reagent (NEB). The transfected cells were treated with or without TNFa for 16 h. The
surface expression of VCAM-1 and ICAM-1 was detected by cell ELISA. Data were represented as mean ± S.D., n = 3, *P < 0.05. (C) Cell viability of the transfected cells was
analyzed by trypan blue exclusion test. The overexpression of MCPIP1 in the transfected cells was monitored by Western blotting with anti-HA antibody. (D) HUVECs were
transiently transfected with HA-MCPIP1 or control vector by electroporation (Amaxa). The transfected cells were treated with or without TNFa for 8 h. The expression of
VCAM-1, ICAM-1, PAI-1 and iNOS were detected using Western blot analysis. The same membrane was probed using anti-actin and anti-HA antibodies. (E) The transfected
HUVECs were treated with or without 10 ng/ml TNFa for 8 h and incubated with PHK67-labeled THP-1 cells for another 1 h. Following washing, attached cells were visualized
by ﬂuorescent microscopy (left) or determined by ﬂuorometry (right). Data were represented as mean ± S.D., n = 3. *P < 0.05 vs treated vector group. (F) HUVECs were seeded
into 96-well plate and transfected with or without 0.1, 0.2 and 0.5 lg/well of HA-MCPIP1. The transfected HUVECs were treated with or without 10 ng/ml TNFa for 8 h and
incubated with PHK67-labeled human CD14+ monocytes for another 1 h. Following washing, attached cells were determined by ﬂuorometry. Data were represented as
mean ± S.D., n = 4. *P < 0.05 vs treated vector group. (G) The HUVECs were treated with or without 10 ng/ml TNFa for 8 h and then added 1, 2, and 5 lg/ml of anti-VCAM
monoclonal antibody for 1 h. The cells then were incubated with PHK67-labeled human CD14+ monocytes for another 1 h. Following washing, attached cells were
determined by ﬂuorometry. Data were represented as mean ± S.D., n = 4. *P < 0.05 vs TNFa only group.
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promoter activation of human VCAM-1 gene
The expression of adhesion molecules VCAM-1 is tightly regu-
lated at both transcriptional and posttranscriptional levels. One re-cent report showed that MCPIP1 (ZC3H12A) functions as a RNase
to regulate mRNA degradation [11]. To explore the mechanisms
of MCPIP1 effect on the expression of VCAM-1, we ﬁrst evaluated
the potential inﬂuence of MCPIP1 on the mRNA degradation of
VCAM-1 in TNFa-stimulated HUVECs. In the experiment shown
Fig. 4. MCPIP1 Knockdown augments TNFa-induced expression of VCAM-1 and the adhesion of THP-1 cells to activated HUVECs. (A) HUVECs were transiently transfected
with short interfering RNA targeting on MCPIP1 (siMCPIP1) or non-speciﬁc short interfering RNA (siControl) by electroporation (Amaxa). The transfected cells were quiescent
for 24 h and then treated with or without TNFa for 8 h. The expression of VCAM-1 and ICAM-1 were detected using Western blot analysis. (B) The intensity of bands was
quantiﬁed by AlphaImage 2200 (AlphaInnotech, CA) and the normalized protein levels were shown in Fig. 4B. *P < 0.01 vs treated siControl group. The data represent three
independent experiments. (C and D) The transfected HUVECs were treated with or without 10 ng/ml TNFa for 8 h and incubated with PHK67-labeled THP-1 cells for another
1 h. Following washing, attached cells were visualized by ﬂuorescent microscopy (C) or determined by ﬂuorometry (D). Data were represented as mean ± S.D., n = 3. *P < 0.05
vs treated siControl group.
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for 8 h and then treated with actinomycin D (5 lg/ml, Sigma).
The RNA was isolated at different time points as indicated. Overex-
pression of MCPIP1 does not affect the mRNA degradation of
VCAM-1. Then, we asked whether MCPIP1 regulate the promoter
activity of VCAM-1. For these studies, we used 1.3 kb fragment
of the human VCAM-1 promoter. The promoter contains all of reg-
ulatory elements necessary for TNFa responsiveness in vivo
[14,16]. As shown in Fig. 5B, forced expression of MCPIP1 dose-
dependently inhibited TNFa-induced promoter activity of VCAM-
1. These results strongly suggest that MCPIP1 negatively regulates
adhesion molecules gene expression by inhibition of their
transcription.
4. Discussion
This study provides evidence that MCPIP1 acts as a negative
regulator for the proinﬂammatory action of TNFa on vascular ECs
in vitro. In particular, MCPIP1 could counteract the increase in
monocyte adhesion to ECs attributable to TNFa, which is crucial
to the inﬂammatory reaction. This anti-inﬂammatory effect of
MCPIP1 is correlated with the inhibition of the induction of
VCAM-1 in response to TNFa. Our data also shows increased
expression of MCPIP1 in atherosclerotic lesion, which underlines
the importance of this novel protein in plaque progression.
Vascular disease such as atherosclerosis involves predomi-
nantly macrophages, T cells, ECs, and smooth muscle cells that
interact with each other in the vessel wall [17]. Recently, we haveidentiﬁed MCPIP1 as a critical regulator of proinﬂammatory activa-
tion of macrophages. In response to inﬂammatory stimuli, such as
LPS and TNFa, the expression of MCPIP1 is markedly induced in
monocytes and macrophages. Indeed, overexpression of MCPIP1
in macrophages has been shown to inhibit inﬂammatory cytokine
expression, but not affect the surface receptors expression as well
as oxidized LDL uptake in these cells. In ECs, MCPIP1 overexpres-
sion has been shown to increase cell survival and angiogenesis
[18]. However, the function of endogenous MCPIP1 in endothelial
activation has not been previously studied. Here, we demonstrate
that MCPIP1 may exert additional activities of potential beneﬁt
for the vessel wall through suppressing monocyte adhesion to
the activated endothelium, which is a key process in the initiation
of atherosclerosis. Thus, we conclude that MCPIP1 may contribute
to the resolution of vascular inﬂammation by constituting a nega-
tive feedback loop in proinﬂammatory activation of macrophages
and ECs.
Interestingly, it is noted that MCPIP1 represses TNFa-induced
VCAM-1 expression, but no signiﬁcant inhibition is seen on
ICAM-1 expression. This is an intriguing observation, although
the basis for this differential inhibition has not been fully eluci-
dated by our studies. Similar phenomenon was also observed by
other group [14].
The exact mechanisms that MCPIP1 reduced the expression of
VCAM-1 are not clear. Recent reports show that MCPIP1 (Zc3h12a)
may contain Rnase activity to promote the mRNA degradation of
some proinﬂammatory cytokines [11,19]. We observed that over-
expression of MCPIP1 did not affect the mRNA degradation of
Fig. 5. MCPIP1 does not affect VCAM-1 mRNA half-life but inhibits its promoter
activity in HUVECs. (A) HUVECs were transiently transfected with EGFP empty
vector or MCPIP1-EGFP by electroporation. After 24 h, the cells were quiescent for
18 h and then treated with TNFa (10 ng/ml) for 8 h and then actinomycin D (5 lg/
ml) was added to stop transcription. RNA was harvested after different time points
as indicated. VCAM-1 and ICAM-1 mRNA levels were examined by Northern blot.
The intensity of bands was quantiﬁed by AlphaImage 2200 (AlphaInnotech, CA). The
value of 0 time point was set as 100% and the values of the other points were
transformed according to 0 point. The data from three independent experiments
were averaged and plotted in the ﬁgure at the bottom of each image. (B) HUVECs
were co-transfected a luciferase reporter plasmid under transcriptional control of
the human VCAM-1 promoter with increasing amount of HA-MCPIP1 (0, 10, 25,
100 ng/per well). After quiescent for 24 h, cells were treated with or without TNFa
(10 ng/ml) as shown and collected for analysis of reporter gene activity 24 h later.
Date represented mean ± S.D., n = 4. The experiment was repeated twice and
showed similar results.
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MCPIP1 inhibited TNFa-induced human VCAM-1 promoter activ-
ity. Ample evidence suggests that proinﬂammatory cytokines such
as TNFa and IL-1b induce nuclear factor-jB (NF-jB) activation in
ECs, which mediates their proatherogenic effects. These include
induction of adhesion molecules such as VCAM-1 and ICAM-1, thus
promoting monocyte adhesiveness to the endothelium. Indeed,
MCPIP1 has been reported to inhibit NF-jB activation by an as
yet unknown mechanism in HEK293 cells and macrophages. Our
recent studies further identiﬁed MCPIP1 as a deubiquitinase to
negatively regulate NF-jB and JNK signaling by targeting to TNF
receptor associate factor family (unpublished data). Taken to-gether, our results suggest that MCPIP1 may inhibits cytokines-ini-
tiated NF-jB signaling and thus limits VCAM-1 gene transcription.
We have conducted serial experiments to understand how
MCPIP1 controls LPS and cytokines-initiated proinﬂammatory sig-
naling pathways and the resulting manuscript has been submitted
to elsewhere. Overall, the data reported herein provide the evi-
dence that the MCPIP1 is a potent negative regulator of the
TNFa-induced EC activation. Thus, speciﬁcally modifying MCPIP1
activity may have potential application in the treatment of inﬂam-
matory vascular disorders.5. Conﬂict of interest
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